PathMaker Neurosystems Announces Publication of First-Ever Study Showing Non-Invasive Clearance of Toxic TDP-43 Protein Aggregates in Preclinical ALS Study

Data ReadoutpositiveMulti-Site DCSPositive

AI Analysis

Summary

PathMaker Neurosystems published results from the first-ever preclinical study demonstrating that its non-invasive Multi-Site DCS technology can reduce toxic TDP-43 protein aggregates in ALS motor neurons.

Clinical Trial Data

Phase

preclinical

Primary Endpoint

Met

Outcome Details

First study showing non-invasive Multi-Site DCS technology can reduce toxic TDP-43 protein in ALS motor neurons

Importance:5/10

Sentiment:

0.70

ALSTDP-43protein aggregationneurodegenerative diseasenon-invasive technologypreclinical

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on October 6, 2026 9:00 AM

Read Original